SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (15052)2/14/1998 4:26:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Bernie, I have posted the abstract. The retinoids were those specific for RARs such as tretinoin and isotretinoin (active ingredients in Retin-A, Renova, Accutane, and Vessinoid). The article itself is fairly long and I just have a hard copy. I'll post more details later. However, for breast cancer (at least in this animal model), the major activity seemed to reside in the ligands that reacted with RXRs (Rexinoids), not RARs (Retinoids). The model has been used to show activity by Tamoxifen as well as Raloxifene (LLY's Evista), both of which are anti-estrogens.



To: Flagrante Delictu who wrote (15052)2/14/1998 4:28:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
When David Robinson mentioned a push toward advanced breast cancer, did he indicate that Ligand had any human data for Targretin (or Panretin, which also has RXR activity, in combination with Tamoxifen)?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News